Moleculin Biotech

Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue remained at zero as expected for this clinical-stage biotech, while GAAP EPS of -$1.40 beat the -$1.55 mean estimate despite a slight miss in EBIT (-$7.56M vs. -$7.39M expected). The pivotal MIRACLE trial demonstrated a complete remission rate of 36-43%, significantly outperforming the 12% control rate. Management confirmed a cash runway into Q1 2027 following a $9.3M post-quarter capital raise, with key unblinded efficacy data expected by Feb 2027.